title: Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease.
abstract: OBJECTIVE
  To assess the combined effect of disease phenotype, smoking and medical therapy [steroid, azathioprine (AZA), AZA/biological therapy] on the probability of disease behavior change in a Caucasian cohort of patients with Crohn's disease (CD).
  
  
  METHODS
  Three hundred and forty well-characterized, unrelated, consecutive CD patients were analyzed (M/F: 155/185, duration: 9.4 +/- 7.5 years) with a complete clinical follow-up. Medical records including disease phenotype according to the Montreal classification, extraintestinal manifestations, use of medications and surgical events were analyzed retrospectively. Patients were interviewed on their smoking habits at the time of diagnosis and during the regular follow-up visits.
  
  
  RESULTS
  A change in disease behavior was observed in 30.8% of patients with an initially non-stricturing, non-penetrating disease behavior after a mean disease duration of 9.0 +/- 7.2 years. In a logistic regression analysis corrected for disease duration, perianal disease, smoking, steroid use, early AZA or AZA/biological therapy use were independent predictors of disease behavior change. In a subsequent Kaplan-Meier survival analysis and a proportional Cox regression analysis, disease location (P = 0.001), presence of perianal disease (P < 0.001), prior steroid use (P = 0.006), early AZA (P = 0.005) or AZA/biological therapy (P = 0.002), or smoking (P = 0.032) were independent predictors of disease behavior change.
  
  
  CONCLUSIONS
  Our data suggest that perianal disease, small bowel disease, smoking, prior steroid use, early AZA or AZA/biological therapy are all predictors of disease behavior change in CD patients.
authors.affiliation: 1st Department of Medicine, Semmelweis University, Koranyi str. 2/A, H-1083 Budapest, Hungary. kislakpet@bel1.sote.hu
authors.forename: Peter Laszlo
authors.initials: PL
authors.lastname: Lakatos
authors.forename: Zsofia
authors.initials: Z
authors.lastname: Czegledi
authors.forename: Tamas
authors.initials: T
authors.lastname: Szamosi
authors.forename: Janos
authors.initials: J
authors.lastname: Banai
authors.forename: Gyula
authors.initials: G
authors.lastname: David
authors.forename: Ferenc
authors.initials: F
authors.lastname: Zsigmond
authors.forename: Tunde
authors.initials: T
authors.lastname: Pandur
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Erdelyi
authors.forename: Orsolya
authors.initials: O
authors.lastname: Gemela
authors.forename: Janos
authors.initials: J
authors.lastname: Papp
authors.forename: Laszlo
authors.initials: L
authors.lastname: Lakatos
mesh_terms: D000328:Adult; D001004:Anus Diseases / Q000188:drug therapy / Q000503:physiopathology; D001379:Azathioprine / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D003424:Crohn Disease / Q000188:drug therapy / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D012044:Regression Analysis; D012907:Smoking; D013256:Steroids / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D007166:Immunosuppressive Agents; D013256:Steroids; D001379:Azathioprine